ClinicalTrials.gg
CompletedNCT03946748Updated Jun 26, 2023Results posted

Study to Evaluate the Efficacy and Safety of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Phase 2 interventional study of REGN3918 in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Regeneron Pharmaceuticals. Completed at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-26.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals — 3 open to participants now, 3 under way, 2 of them phase 3. Hemoglobinuria, Paroxysmal · Regeneron Pharmaceuticals.

Started
2019
with 1 other
Phase 2
3 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, this one is one of 2 that started in 2019, is one of 3 in phase 2, and was the 1st registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

3 of the 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Hemoglobinuria, Paroxysmal by Regeneron Pharmaceuticals, or all of them as a file.
02

Study summary

The primary objective of the study is to demonstrate a reduction in intravascular hemolysis by REGN3918 over 26 weeks of treatment in patients with active PNH who are treatment-naive to complement inhibitor therapy or have not recently received complement inhibitor therapy.

The secondary objectives of the study are:

  • To evaluate the safety and tolerability of REGN3918.
  • To evaluate the effect of REGN3918 on parameters of intravascular hemolysis
  • To assess the concentrations of total REGN3918 in serum.
  • To evaluate the incidence of treatment-emergent anti-drug antibodies to REGN3918 over time
  • To evaluate the effect of REGN3918 on patient-reported outcomes (PROs) measuring fatigue and health-related quality of life
03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH) confirmed by high-sensitivity flow cytometry
  • PNH granulocytes > 10% at screening visit
  • Active disease, as defined by the presence of 1 or more PNH-related signs or symptoms (eg, fatigue, hemoglobinuria, abdominal pain, shortness of breath [dyspnea], anemia [ \<10 g/dL], history of a MAVE [including thrombosis], dysphagia, or erectile dysfunction) or history of red blood cell (RBC) transfusion due to PNH within 3 months of screening.
  • Lactate dehydrogenase (LDH) level ≥ 2 × (ULN) at screening visit.

Key Exclusion Criteria:

  • Prior treatment with a complement inhibitor either within 6 months prior to screening visit or at any time where the patient was to complement inhibitor therapy, in the opinion of the investigator (with the exception of eculizumab refractory patients due to the C5 variant R885H/C)
  • History of bone marrow transplantation
  • Body weight \< 40 kilograms at screening visit
  • Peripheral blood (ANC) \<500/μL [\<0.5 x 109/L] or peripheral blood count \<50,000/μL
  • Documented history of systemic fungal disease or unresolved tuberculosis, or evidence of active or latent tuberculosis infection (LTBI) during screening period
  • Any for receiving Neisseria meningitidis vaccination and antibiotic prophylaxis therapy as recommended in the study
  • Any active, ongoing infection within 2 weeks of screening or during the screening period
  • Any abnormality identified at the time of screening that in the judgment of the Investigator or any sub-Investigator would preclude safe completion of the study or constrain endpoints assessment such as major systemic diseases, or patients with short
  • Women who are pregnant, breastfeeding, or who have a positive pregnancy test at screening visit or day 1

NOTE: Other protocol defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    REGN3918

    Cohort A (Dose Confirmation) If a decision is made to expand Cohort A, patients will be assigned to Cohort A. Cohort B (Dose Expansion) If a decision is made to progress to Cohort B, patients will be assigned to Cohort B.

    Drug: REGN3918

Interventions

  • Single intravenous (IV) dose, then a subcutaneous (SC) dose once weekly (QW).

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis

    Participants were considered to have had adequate control of intravascular hemolysis if all of their lactose dehydrogenase (LDH) readings from Week 4 through Week 26 inclusive had values less than or equal to ≤ 1.5 × upper limit of normal (ULN). Participants must have greater than or equal to (≥) 50 percent (%) of scheduled LDH measures in those weeks, must not have had more than (\>) 2 consecutive visits without LDH measures, must not have experienced breakthrough hemolysis, and must not have discontinued study treatment early. Participants were considered not to have had adequate control of intravascular hemolysis if they failed any of these criteria.

    Time frame: Week 4 through Week 26

  2. Percentage of Participants Who Achieved Transfusion Avoidance

    Transfusion avoidance was defined as not having received red blood cell (RBC) transfusion during the first 26 weeks. A transfusion was counted only if it was per-protocol, that is, it followed the predefined transfusion algorithm: RBC transfusion due to a post-baseline hemoglobin level \< 9 grams per deciliter (g/dL) (with anemia symptoms) or a post-baseline hemoglobin level \< 7 g/dL (without anemia symptoms).

    Time frame: Up to 26 Weeks

Secondary outcomes

  1. Percentage of Participants Who Had Breakthrough Hemolysis (BTH)

    Breakthrough hemolysis was defined as the measurement of LDH ≥ 2 ULN concomitant with associated signs or symptoms at any time subsequent to an initial achievement of disease control (i.e., LDH ≤ 1.5 ULN).

    Time frame: Baseline up to 26 Weeks

  2. Percentage of Participants Who Achieved Normalization of Intravascular Hemolysis

    A participant was considered to have achieved normalization of intravascular hemolysis if their LDH readings between Week 4 through Week 26 inclusive had values ≤ 1.0 ULN. A participant must have ≥ 50% of scheduled LDH measures in those weeks, must not have had \> 2 consecutive visits without LDH measures, must not have experienced breakthrough hemolysis, and must not have discontinued study treatment early. A participant was considered not to have achieved normalization of intravascular hemolysis if they failed any of these criteria.

    Time frame: Week 4 through Week 26

  3. Time to First Lactate Dehydrogenase (LDH) ≤1.5 x ULN

    A time-to-first-event analysis was used to estimate the proportion of participants achieving transfusion avoidance at Week 26.

    Time frame: Up to Week 26

  4. Percentage of Days With LDH ≤ 1.5 ULN From Week 4 Through Week 26

    Percentage of days was calculated as number of days with LDH ≤ 1.5 x ULN divided by the participant's total treatment duration (total number of days on treatment from Week 4 through Week 26). LDH ≤ 1.5 x ULN was used as an indicator of adequate control of intravascular hemolysis.

    Time frame: Week 4 through Week 26

  5. Change From Baseline in LDH Levels at Week 26

    Change from baseline in LDH levels at Week 26 was reported.

    Time frame: Baseline, Week 26

  6. Percent Change From Baseline in LDH Levels at Week 26

    Percent change from baseline in LDH levels at Week 26 was reported.

    Time frame: Baseline, Week 26

  7. Rate of Transfusion With Red Blood Cells (RBCs)

    The rate of transfusion with RBCs for a participant was the total number of transfusions divided by total person-years of time on treatment.

    Time frame: Baseline up to Week 26

  8. Number of Units of Transfusion With RBCs

    Transfusions with RBCs proceeded according to the following predefined criteria that triggered a transfusion; however, the actual number of units to be transfused is at the discretion of the investigator: • Transfuse with RBC(s) if the post-baseline hemoglobin level is \<9 g/dL with symptoms resulting from anemia or • Transfuse with RBC(s) if the post-baseline hemoglobin level is \<7 g/dL.

    Time frame: Baseline up to Week 26

  9. Change From Baseline in RBC Hemoglobin Levels at Week 26

    Hemoglobin levels in participants with PNH was measured. Change from baseline in RBC hemoglobin at Week 26 was reported.

    Time frame: Baseline, Week 26

  10. Change From Baseline in Free Hemoglobin Levels at Week 26

    Change from baseline in free hemoglobin levels at Week 26 was assessed.

    Time frame: Baseline, Week 26

  11. Change From Baseline in Total Complement Hemolytic Activity Assay (CH50) at Week 26

    Change from baseline in total CH50 at Week 26 was reported. Here "International units per milliliter" was abbreviated as "IU/mL".

    Time frame: Baseline, Week 26

  12. Percent Change From Baseline in CH50 up to Week 26

    Percent change from baseline in CH50 up to Week 26 was reported.

    Time frame: Baseline up to Week 26

  13. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 26

    The FACIT-F was a 13-item, self-reported PRO measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire was part of the FACIT measurement system, a compilation of questions measuring health-related QoL in participants with cancer and other chronic illnesses. The FACIT-fatigue assessed the level of fatigue using a 4-point Likert scale ranging from 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much) The sum of all responses resulted in the FACIT-F score for a total possible score of 0 to 52, with higher scores indicated greater fatigue.

    Time frame: Baseline, Week 26

  14. Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30) at Week 26

    The EORTC QLQ-C30 was a 30-item questionnaire used to assess symptoms and side effects of treatment and the impact on everyday life. It consists of 15 domains: 5 multi-item functioning scales (physical, role, social, emotional and cognitive), answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score ranges from 0-100 with a higher score indicates higher level of functioning and a better QoL. A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent). Each score ranges from 0-100 with a higher score indicates a better QoL. 9 symptom scales (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact), answered on a 4-point scale (1=Not at all, 2=A Little, 3=Quite a Bit, 4=Very Much). Each score ranges from 0 to 100 with a higher score indicates a higher level of symptoms, and a negative change from baseline indicates an improvement in symptoms.

    Time frame: Baseline, Week 26

  15. Change From Baseline in European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Index Score

    EQ-5D-3L was a self-administered standardized instrument for use as measure of health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension rated on 3 levels scale: 1 (no problems), 2 (some problems), 3 (extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" to severe problems in 5 dimensions. EQ-5D index calculated by applying preference-based weights (tariffs) to scores of five health state dimensions. Index values range from -1 to 1, with 0 representing a health state equivalent to death and 1 representing perfect health. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best).

    Time frame: Baseline, Week 26

  16. Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Week 26

    The EQ-5D-3L was a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. The EQ-5D-3L includes a visual analog scale (VAS) which is a vertical scale with numbers ranging from 0 to 100. Participants were asked to draw a line to the place on the scale that best represented how good or bad his health was on that day. The worst state a participant can imagine was marked zero, and the best state the participant can imagine was marked 100. Mean change in VAS score from baseline was reported.

    Time frame: Baseline, Week 26

  17. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as AEs that developed or worsened during the on-treatment period. SAE was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to Week 26

  18. Number of Participants With TEAEs Based on Severity

    An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Severity of AEs was graded according to the following scale, Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

    Time frame: Baseline up to Week 26

  19. Number of Participants With Clinically Meaningful Changes in Clinical Laboratory Parameters

    Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with potential clinically significant changes in laboratory parameters which were deemed clinically meaningful by the investigator were reported.

    Time frame: Baseline up to Week 26

  20. Number of Participants With Clinically Meaningful Changes in Vital Signs

    Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with potential clinically meaningful changes in vital signs which were deemed clinically significant by the investigator were reported.

    Time frame: Baseline up to Week 26

  21. Number of Participants With Clinically Meaningful Changes in 12-lead Electrocardiograms (ECGs)

    12-lead ECGs were evaluated. Any change in ECG assessments which are deemed clinically meaningful by the investigator were reported.

    Time frame: Baseline up to Week 26

  22. Serum Concentrations of Total REGN3918

    Serum Concentrations of total REGN3918 was reported.

    Time frame: Pre-dose (Day 0), End of infusion at Days 0, 2, 7, 28, 56, 84, 112, 140, and 182

  23. Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) Response to REGN3918

    Number of Participants with treatment-emergent ADA response to REGN3918 was reported.

    Time frame: Baseline up to Week 26

07

Results

Posted Jun 26, 2023

Participant flow

Participant flow — Overall Study
MilestoneREGN3918
Started24
Completed24
Not completed0

Outcome measures

PrimaryPercentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis

Participants were considered to have had adequate control of intravascular hemolysis if all of their lactose dehydrogenase (LDH) readings from Week 4 through Week 26 inclusive had values less than or equal to ≤ 1.5 × upper limit of normal (ULN). Participants must have greater than or equal to (≥) 50 percent (%) of scheduled LDH measures in those weeks, must not have had more than (\>) 2 consecutive visits without LDH measures, must not have experienced breakthrough hemolysis, and must not have discontinued study treatment early. Participants were considered not to have had adequate control of intravascular hemolysis if they failed any of these criteria.

Time frame:
Week 4 through Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis
Percentage of ParticipantsREGN3918
Percentage of Participants Who Achieved Adequate Control of Intravascular Hemolysis75.0 (57.7 to 92.3)
PrimaryPercentage of Participants Who Achieved Transfusion Avoidance

Transfusion avoidance was defined as not having received red blood cell (RBC) transfusion during the first 26 weeks. A transfusion was counted only if it was per-protocol, that is, it followed the predefined transfusion algorithm: RBC transfusion due to a post-baseline hemoglobin level \< 9 grams per deciliter (g/dL) (with anemia symptoms) or a post-baseline hemoglobin level \< 7 g/dL (without anemia symptoms).

Time frame:
Up to 26 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Transfusion Avoidance
Percentage of ParticipantsREGN3918
Percentage of Participants Who Achieved Transfusion Avoidance87.5 (74.3 to 100.0)
SecondaryPercentage of Participants Who Had Breakthrough Hemolysis (BTH)

Breakthrough hemolysis was defined as the measurement of LDH ≥ 2 ULN concomitant with associated signs or symptoms at any time subsequent to an initial achievement of disease control (i.e., LDH ≤ 1.5 ULN).

Time frame:
Baseline up to 26 Weeks
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Had Breakthrough Hemolysis (BTH)
Percentage of ParticipantsREGN3918
Percentage of Participants Who Had Breakthrough Hemolysis (BTH)0 (0 to 0)
SecondaryPercentage of Participants Who Achieved Normalization of Intravascular Hemolysis

A participant was considered to have achieved normalization of intravascular hemolysis if their LDH readings between Week 4 through Week 26 inclusive had values ≤ 1.0 ULN. A participant must have ≥ 50% of scheduled LDH measures in those weeks, must not have had \> 2 consecutive visits without LDH measures, must not have experienced breakthrough hemolysis, and must not have discontinued study treatment early. A participant was considered not to have achieved normalization of intravascular hemolysis if they failed any of these criteria.

Time frame:
Week 4 through Week 26
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Achieved Normalization of Intravascular Hemolysis
Percentage of ParticipantsREGN3918
Percentage of Participants Who Achieved Normalization of Intravascular Hemolysis16.7 (1.8 to 31.6)
SecondaryTime to First Lactate Dehydrogenase (LDH) ≤1.5 x ULN

A time-to-first-event analysis was used to estimate the proportion of participants achieving transfusion avoidance at Week 26.

Time frame:
Up to Week 26
Reported as:
Mean · Days
Time to First Lactate Dehydrogenase (LDH) ≤1.5 x ULN
DaysREGN3918
Time to First Lactate Dehydrogenase (LDH) ≤1.5 x ULN13.625 ± 3.6927
SecondaryPercentage of Days With LDH ≤ 1.5 ULN From Week 4 Through Week 26

Percentage of days was calculated as number of days with LDH ≤ 1.5 x ULN divided by the participant's total treatment duration (total number of days on treatment from Week 4 through Week 26). LDH ≤ 1.5 x ULN was used as an indicator of adequate control of intravascular hemolysis.

Time frame:
Week 4 through Week 26
Reported as:
Mean · Percentage of Days
Percentage of Days With LDH ≤ 1.5 ULN From Week 4 Through Week 26
Percentage of DaysREGN3918
Percentage of Days With LDH ≤ 1.5 ULN From Week 4 Through Week 2693.4 ± 18.76
SecondaryChange From Baseline in LDH Levels at Week 26

Change from baseline in LDH levels at Week 26 was reported.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Units per liter (U/L)
Change From Baseline in LDH Levels at Week 26
Units per liter (U/L)REGN3918
Change From Baseline in LDH Levels at Week 26-5.070 ± 0.1467
SecondaryPercent Change From Baseline in LDH Levels at Week 26

Percent change from baseline in LDH levels at Week 26 was reported.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in LDH Levels at Week 26
Percent ChangeREGN3918
Percent Change From Baseline in LDH Levels at Week 26-81.72 ± 1.847
SecondaryRate of Transfusion With Red Blood Cells (RBCs)

The rate of transfusion with RBCs for a participant was the total number of transfusions divided by total person-years of time on treatment.

Time frame:
Baseline up to Week 26
Reported as:
Number · Infusions Per Participant Year
Rate of Transfusion With Red Blood Cells (RBCs)
Infusions Per Participant YearREGN3918
Rate of Transfusion With Red Blood Cells (RBCs)1.039 (0.187 to 5.772)
SecondaryNumber of Units of Transfusion With RBCs

Transfusions with RBCs proceeded according to the following predefined criteria that triggered a transfusion; however, the actual number of units to be transfused is at the discretion of the investigator: • Transfuse with RBC(s) if the post-baseline hemoglobin level is \<9 g/dL with symptoms resulting from anemia or • Transfuse with RBC(s) if the post-baseline hemoglobin level is \<7 g/dL.

Time frame:
Baseline up to Week 26
Reported as:
Mean · Number of units of transfusions of RBC
Number of Units of Transfusion With RBCs
Number of units of transfusions of RBCREGN3918
Number of Units of Transfusion With RBCs3.625 ± 4.274
SecondaryChange From Baseline in RBC Hemoglobin Levels at Week 26

Hemoglobin levels in participants with PNH was measured. Change from baseline in RBC hemoglobin at Week 26 was reported.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · grams per liter (g/L)
Change From Baseline in RBC Hemoglobin Levels at Week 26
grams per liter (g/L)REGN3918
Change From Baseline in RBC Hemoglobin Levels at Week 2615.0 ± 3.24
SecondaryChange From Baseline in Free Hemoglobin Levels at Week 26

Change from baseline in free hemoglobin levels at Week 26 was assessed.

Time frame:
Baseline, Week 26
Reported as:
Mean · milligrams per deciliter (mg/dL)
Change From Baseline in Free Hemoglobin Levels at Week 26
milligrams per deciliter (mg/dL)REGN3918
Change From Baseline in Free Hemoglobin Levels at Week 26-9.19 ± 16.264
SecondaryChange From Baseline in Total Complement Hemolytic Activity Assay (CH50) at Week 26

Change from baseline in total CH50 at Week 26 was reported. Here "International units per milliliter" was abbreviated as "IU/mL".

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · IU/mL
Change From Baseline in Total Complement Hemolytic Activity Assay (CH50) at Week 26
IU/mLREGN3918
Change From Baseline in Total Complement Hemolytic Activity Assay (CH50) at Week 26-236.6 ± 0.65
SecondaryPercent Change From Baseline in CH50 up to Week 26

Percent change from baseline in CH50 up to Week 26 was reported.

Time frame:
Baseline up to Week 26
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in CH50 up to Week 26
Percent ChangeREGN3918
Percent Change From Baseline in CH50 up to Week 26-99.99 ± 0.243
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 26

The FACIT-F was a 13-item, self-reported PRO measure assessing an individual's level of fatigue during their usual daily activities over the past week. This questionnaire was part of the FACIT measurement system, a compilation of questions measuring health-related QoL in participants with cancer and other chronic illnesses. The FACIT-fatigue assessed the level of fatigue using a 4-point Likert scale ranging from 0 (not at all), 1 (a little bit), 2 (somewhat), 3 (quite a bit), 4 (very much) The sum of all responses resulted in the FACIT-F score for a total possible score of 0 to 52, with higher scores indicated greater fatigue.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 26
Score on a ScaleREGN3918
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Week 269.9 ± 1.52
SecondaryChange From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30) at Week 26

The EORTC QLQ-C30 was a 30-item questionnaire used to assess symptoms and side effects of treatment and the impact on everyday life. It consists of 15 domains: 5 multi-item functioning scales (physical, role, social, emotional and cognitive), answered on a 4-point scale (1=Not at all,2=A Little,3=Quite a Bit,4=Very Much). Each score ranges from 0-100 with a higher score indicates higher level of functioning and a better QoL. A global health status/QoL scale that was answered on a 7-point scale (1=Very Poor to 7=Excellent). Each score ranges from 0-100 with a higher score indicates a better QoL. 9 symptom scales (Fatigue, Nausea and Vomiting, Pain, Dyspnea, Insomnia, Appetite Loss, Constipation, Diarrhea, Financial Impact), answered on a 4-point scale (1=Not at all, 2=A Little, 3=Quite a Bit, 4=Very Much). Each score ranges from 0 to 100 with a higher score indicates a higher level of symptoms, and a negative change from baseline indicates an improvement in symptoms.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-core 30 (EORTC QLQ-C30) at Week 26
Score on a ScaleREGN3918
Global Health status/quality: Change at Week 2612.509 ± 3.2286
Physical Functioning: Change at Week 2617.511 ± 2.6767
Emotional Functioning: Change at Week 2614.457 ± 3.8645
Social Functioning: Change at Week 2615.846 ± 3.8036
Fatigue: Change at Week 26-18.904 ± 2.9899
Pain: Change at Week 26-13.537 ± 3.0315
Dyspnea: Change at Week 26-15.874 ± 4.7953
Cognitive Functioning: Change at Week 269.840 ± 2.9710
SecondaryChange From Baseline in European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Index Score

EQ-5D-3L was a self-administered standardized instrument for use as measure of health outcome. It comprised 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension rated on 3 levels scale: 1 (no problems), 2 (some problems), 3 (extreme problems). The summed score ranges from 5-15 with "5" corresponding to no problems and "15" to severe problems in 5 dimensions. EQ-5D index calculated by applying preference-based weights (tariffs) to scores of five health state dimensions. Index values range from -1 to 1, with 0 representing a health state equivalent to death and 1 representing perfect health. Total index EQ-5D-3L summary score was weighted with a range of -0.594 (worst) to 1.0 (best).

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Index Score
Score on a ScaleREGN3918
Change From Baseline in European Quality of Life-5 Dimensions-3 Level (EQ-5D-3L) Index Score0.136 ± 0.0238
SecondaryChange From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Week 26

The EQ-5D-3L was a standardized instrument for use as a measure of health outcome and was administered to all participants to assess the effect of the treatment on the participants' quality of life. The EQ-5D-3L includes a visual analog scale (VAS) which is a vertical scale with numbers ranging from 0 to 100. Participants were asked to draw a line to the place on the scale that best represented how good or bad his health was on that day. The worst state a participant can imagine was marked zero, and the best state the participant can imagine was marked 100. Mean change in VAS score from baseline was reported.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Score on a Scale
Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Week 26
Score on a ScaleREGN3918
Change From Baseline in EQ-5D-3L Visual Analogue Scale (VAS) at Week 268.4 ± 2.18
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. TEAEs was defined as AEs that developed or worsened during the on-treatment period. SAE was defined as any untoward medical occurrence that resulted in any of following outcomes: death, life-threatening, required initial/prolonged in-participant hospitalization, persistent/significant disability/incapacity, congenital anomaly/birth defect/considered as medically important event. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsREGN3918
Participants with TEAEs21
Participants with Serious TEAEs0
SecondaryNumber of Participants With TEAEs Based on Severity

An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. Severity of AEs was graded according to the following scale, Mild: event that does not generally interfere with usual activities of daily living; Moderate: event that interferes with usual activities of daily living, causing discomfort, permanent risk of harm; Severe: AE that interrupts usual activities of daily living, significantly affects clinical status, or may require intensive therapeutic intervention.

Time frame:
Baseline up to Week 26
Reported as:
Number · Participants
Number of Participants With TEAEs Based on Severity
ParticipantsREGN3918
Participants with Mild TEAEs13
Participants with Moderate TEAEs6
Participants with Severe TEAEs2
SecondaryNumber of Participants With Clinically Meaningful Changes in Clinical Laboratory Parameters

Clinical laboratory parameters included biochemistry, hematology and urinalysis. Number of participants with potential clinically significant changes in laboratory parameters which were deemed clinically meaningful by the investigator were reported.

Time frame:
Baseline up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes in Clinical Laboratory Parameters
ParticipantsREGN3918
Hematology13
Chemistry17
Urinalysis0
SecondaryNumber of Participants With Clinically Meaningful Changes in Vital Signs

Vital sign assessments included pulse rate, blood pressure (systolic and diastolic blood pressure) and body temperature. Number of participants with potential clinically meaningful changes in vital signs which were deemed clinically significant by the investigator were reported.

Time frame:
Baseline up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes in Vital Signs
ParticipantsREGN3918
Number of Participants With Clinically Meaningful Changes in Vital Signs12
SecondaryNumber of Participants With Clinically Meaningful Changes in 12-lead Electrocardiograms (ECGs)

12-lead ECGs were evaluated. Any change in ECG assessments which are deemed clinically meaningful by the investigator were reported.

Time frame:
Baseline up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Clinically Meaningful Changes in 12-lead Electrocardiograms (ECGs)
ParticipantsREGN3918
Number of Participants With Clinically Meaningful Changes in 12-lead Electrocardiograms (ECGs)0
SecondarySerum Concentrations of Total REGN3918

Serum Concentrations of total REGN3918 was reported.

Time frame:
Pre-dose (Day 0), End of infusion at Days 0, 2, 7, 28, 56, 84, 112, 140, and 182
Reported as:
Mean · Milligram/liter (mg/L)
Serum Concentrations of Total REGN3918
Milligram/liter (mg/L)REGN3918
At Day 0 (Pre-dose)0 ± 0
At Day 0 (End of Infusion)605 ± 214
At Day 2 (End of Infusion)429 ± 159
At Day 7 (End of Infusion)292 ± 80.5
At Day 28 (End of Infusion)324 ± 97.5
At Day 56 (End of Infusion)368 ± 148
At Day 84 (End of Infusion)363 ± 152
At Day 112 (End of Infusion)379 ± 186
At Day 140 (End of Infusion)430 ± 225
At Day 182 (End of Infusion)435 ± 221
SecondaryNumber of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) Response to REGN3918

Number of Participants with treatment-emergent ADA response to REGN3918 was reported.

Time frame:
Baseline up to Week 26
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) Response to REGN3918
ParticipantsREGN3918
Number of Participants With Treatment-emergent Anti-Drug Antibodies (ADA) Response to REGN39180

Adverse events

Collected over From first dose to Week 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
REGN39180/24 (0%)0/24 (0%)13/24 (54.2%)
Most frequent other events
Most frequent other events
EventREGN3918
HeadacheNervous system disorders9/24
Abdominal painGastrointestinal disorders3/24
NasopharyngitisInfections and infestations3/24
Injection site reactionGeneral disorders3/24
NauseaGastrointestinal disorders2/24
Upper respiratory tract infectionInfections and infestations2/24

Baseline characteristics

The safety analysis set (SAF) included all enrolled participants who received any study drug.

Age, Continuous
Age, Continuous(Years)REGN3918
Mean45.4 ± 17.28
Sex: Female, Male
Sex: Female, Male(Participants)REGN3918
Female11
Male13
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)REGN3918
Hispanic or Latino0
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)REGN3918
American Indian or Alaska Native0
Asian21
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported1
08

Study locations

12 sites
  • Regeneron Study Site
    Sha Tin, Hong Kong
  • Regeneron Study Site
    Budapest, 1083, Hungary
  • Regeneron Study Site
    Kaposvár, 4400, Hungary
  • Regeneron Study Site
    Seoul, 03080, Korea, Republic of
  • Regeneron Study Site
    Seoul, 03722, Korea, Republic of
  • Regeneron Study Site
    Seoul, 05030, Korea, Republic of
  • Regeneron Study Site
    Seoul, 06351, Korea, Republic of
  • Regeneron Study Site
    Seoul, 07985, Korea, Republic of
  • Regeneron Study Site
    Kota Bharu, Kelantan 15586, Malaysia
  • Regeneron Study Site
    Sibu, Sarawak 96000, Malaysia
  • Regeneron Study Site
    Kuala Terengganu, Terengganu 20400, Malaysia
  • Regeneron Study Site
    Airdrie, Lanarkshire ML60JS, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jun 2021, 24 months.

Results were first posted in Jun 2023, 2 years after primary completion.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 24 months is above that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2019
First posted
May 13, 2019
StartActual
May 16, 2019
Primary completionActual
Jun 9, 2021
CompletionActual
Jun 10, 2021
Results first posted
Jun 26, 2023
Last update
Jun 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03946748
Responsible party
Sponsor
First posted
May 13, 2019
Start date
May 16, 2019
Primary completion
Jun 9, 2021
Completion
Jun 10, 2021
Results posted
Jun 26, 2023
Last update
Jun 26, 2023

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pozelimab

Start the discussion